Analysis of change in blood leukocyte count by anticoagulant in leukocytapheresis for rheumatoid arthritis

Analysis of change in blood leukocyte count by anticoagulant in leukocytapheresis for rheumatoid arthritis - Analysis of change in blood leukocyte count in leukocytapheresis for rheumatoid arthritis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031850

Enrollment

Registered

2018-03-26

Start date

2006-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

leukocytapheresis

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who meet the ACR criteria for rheumatoid arthritis. Patients who are resistant to 2 or more DMARDs or can not be administered DMARDs or biopharmaceuticals because of concomitant disease or infection. Patients who's disease activity remain high for at least two weeks preceeding LCAP initiation even in the presence of conventional treatment.

Exclusion criteria

Exclusion criteria: Patients who have active infections.

Design outcomes

Primary

Measure	Time frame
blood leukocyte count at baseline, finished and 4weeks after leukocytapheresis.	—

Secondary

Measure	Time frame
Swollen joint count, Tender joint count, C-reactive protein, DAS28(CRP) at baseline, finished and 4weeks after leukocytapheresis.	—

Countries

Japan

Contacts

Public ContactKen Yamaji

Juntendo University School of Medicine Department of Internal Medicine and Rheumatology

kyamaji@juntendo.ac.jp81-3-5802-1067

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026